NCT05522881Recruiting
The Registry Study of Genetic Alterations of Oropharyngeal Cancer in Taiwan
Source: ClinicalTrials.gov · Last updated 2 Jul 2026
Brief summary (registry, in English)
We will use the next-generation sequencing (NGS) technology to identify genomic alterations of Taiwanese HPV positive and negative oropharyngeal squamous cell carcinoma (OPSCC) for novel biomarker development and the study design of potential clinical trials or translational research.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 410 (estimated)
- First submitted
- 23 Aug 2022
- Start date
- 25 Nov 2022
- Primary completion date
- Dec 2029
- Lead sponsor
- National Health Research Institutes, Taiwan
- Diseases
- Head and neck cancer
- NCT number
- NCT05522881
What you commit to
- Study type: Observational
- Planned participants: 410
- From 25 Nov 2022 to the primary completion date, Dec 2029
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Having a known additional malignancy that is progressing or has required active treatment within the past 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., cervical carcinoma in situ) that have undergone potentially curative therapy are not excluded
Other
- Inability to cooperate by providing a complete medical history
- No available tumor tissues for genetic testing
- Undesirable compliance
Who the study is looking for
- Ages 20 and above
- Pathological reported as squamous cell carcinoma of head and neck
- Available p16 immunohistochemical staining status (restricted to the OPSCC subgroup)
- Participants have both archival tumor tissues from the primary head and neck SCC and from the first recurrent tumor (for the recurrence subgroup)
- Recurrence status is defined as the reappearance of the disease occurring more than 6 months following curative surgery and/or chemoradiotherapy in the recurrence subgroup
- Willingness to provide archival or newly obtained tumor tissues for current study proposal
- Life expectancy more than 3 months
- Patients fully understand the protocol with the willingness to have regular follow-up
Age in the registry: 20 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kaohsiung Medical University Chung-Ho Memorial Hospital Coordinator of this site? Confirm its status | Kaohsiung City | Taiwan | Recruiting |
| Kaohsiung Veterans General Hospital Coordinator of this site? Confirm its status | Kaohsiung City | Taiwan | Recruiting |
| China Medical University Hospital Coordinator of this site? Confirm its status | Taichung | Taiwan | Recruiting |
| Taichung Veterans General Hospital Coordinator of this site? Confirm its status | Taichung | Taiwan | Recruiting |
| National Cheng Kung University Hospital Coordinator of this site? Confirm its status | Tainan | Taiwan | Recruiting |
| Pei-Jen Alex Lou Coordinator of this site? Confirm its status | Taipei | Taiwan | Recruiting |
| Taipei Veterans General Hospital Coordinator of this site? Confirm its status | Taipei | Taiwan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.